School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Precipio, Inc. PRPO

Healthcare · Diagnostics & Research

$23.12last close 2026-10-09 · market cap $41.39M · delayed data

Trailing returns

1M-9.69%
3M-12.69%
6M-16.89%
1Y+17.60%
5Y-54.67%

Basis: Adjusted daily closes.

What it does

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages.

Open PRPO in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies